News & Updates

BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization
BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization
06 May 2025 byKanas Chan

BNT162b2 JN.1-adapted vaccine provides protection against COVID-19–related hospitalization in Europe, a case-control study using the id.DRIVE platform has shown.

BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization
06 May 2025
MSC therapy delivers long-term benefit in severe COVID-19
MSC therapy delivers long-term benefit in severe COVID-19
02 May 2025 byAudrey Abella

A recent study suggests patients with severe COVID-19 may benefit from human mesenchymal stem cell (MSC) therapy.

MSC therapy delivers long-term benefit in severe COVID-19
02 May 2025
Single-dose baloxavir reduces household transmission of influenza
Single-dose baloxavir reduces household transmission of influenza
30 Apr 2025 byNatalia Reoutova

A single dose of baloxavir given to an index patient (IP) reduces the odds of influenza transmission to untreated household contacts (HHCs) by 32 percent vs placebo, according to the results of the phase IIIb CENTERSTONE trial.

Single-dose baloxavir reduces household transmission of influenza
30 Apr 2025
SOF/VEL combo improves well-being of children with CHC
SOF/VEL combo improves well-being of children with CHC
27 Apr 2025 byStephen Padilla

In children with chronic hepatitis C (CHC), effective treatment with sofosbuvir/velpatasvir (SOF/VEL) results in improvements in certain areas of their well-being at 1 year. This suggests some patient-reported outcomes (PRO) benefits of direct-acting antiviral (DAA) therapy. However, the parents’ proxy reports show a decrease in the patients’ school functioning.

SOF/VEL combo improves well-being of children with CHC
27 Apr 2025